| 1. Mohler 3rd ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, Darapladib Investigators. (2008) The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.. J Am Coll Cardiol, 51 (17): (1632-41). [PMID:18436114] [10.1021/op500134e] |
| 2. Wilensky RL, Macphee CH. (2009) Lipoprotein-associated phospholipase A(2) and atherosclerosis.. Curr Opin Lipidol, 20 (5): (415-20). [PMID:19667981] [10.1021/op500134e] |
| 3. O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, Hochman J, Maggioni AP, Bode C, Weaver D, Johnson JL et al.. (2011) Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.. Am Heart J, 162 (4): (613-619.e1). [PMID:21982651] [10.1021/op500134e] |
| 4. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG et al.. (2014) Darapladib for preventing ischemic events in stable coronary heart disease.. N Engl J Med, 370 (18): (1702-11). [PMID:24678955] [10.1021/op500134e] |
| 5. O'Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP et al.. (2014) Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.. JAMA, 312 (10): (1006-15). [PMID:25173516] [10.1021/op500134e] |
| 6. Staurenghi G, Ye L, Magee MH, Danis RP, Wurzelmann J, Adamson P, McLaughlin MM, Darapladib DME Study Group. (2015) Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.. Ophthalmology, 122 (5): (990-6). [PMID:25749297] [10.1021/op500134e] |
| 7. Sofogianni A, Alkagiet S, Tziomalos K. (2018) Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease.. Curr Pharm Des, 24 (3): (291-296). [PMID:29332572] [10.1021/op500134e] |
| 8. Tian Y, Jia H, Li S, Wu Y, Guo L, Tan G, Li B. (2017) The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.. Medicine (Baltimore), 96 (51): (e9413). [PMID:29390564] [10.1021/op500134e] |
| 9. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA et al.. (1995) Anti-inflammatory properties of a platelet-activating factor acetylhydrolase.. Nature, 374 (6522): (549-53). [PMID:7700381] [10.1021/op500134e] |
A2213306